HALT · TUE SEP 15 2026

Why BIVI was halted on Sep 15 2026: phase 2 trial results

BIVI+7.0%on Tue Sep 15 2026

BioVie, Inc. Common Stock was up 7.0% on the day at $1.92, ranked #178 on 1.0× its usual five-minute volume, when TapeRank recorded this trading halt at 07:25 ET during the pre-market session when it was halted.

THE DAY ON THE LIST · 1 EVENT

  1. 07:25 ET
    HALT · PRE-MARKET

    HALTED AT $1.92 · ▲ 7.0% ON THE DAY · 1.0× 5M RVOL · RANK #178

    JUSTIFIEDCONFIDENCE5/5

    BIVI is up 14% pre-market after reporting positive Phase 2 Long COVID subgroup results and an advantage over placebo on 21 of 22 endpoints. The move is supported by a material clinical readout, although the overall population did not achieve statistical significance and the strongest results were limited to prespecified subgroups.

    WHYA 14% pre-market gain is proportionate to a mixed but directionally positive Phase 2 readout, rather than obviously exceeding the news.
    ANALYZED 08:01 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNA
    THE ROW AND SESSION LEVELS AT 07:25 ET
    LAST1.92
    DAY▲ 7.0%
    5 MIN▲ 0.02%
    5M RVOL1.0×
    5M $VOL$6K
    FLOAT*8.5M
    RANK#178
    SESSIONPRE-MARKET
    VWAP1.88
    HOD1.98
    LOD1.77
    OR HIGH—
    OR LOW—
    PREV CLOSE1.79
    PM HIGH1.98
    PM LOW1.77
    GAP▲ 7.04% (indicated)

    * FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE

    — MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO

THE SESSION

  • 07:25 ETHalted (T1); resumed 08:00 ET, after 35 minutes
  • 09:30 ETOpened at $1.90, +6.2% on the previous close of $1.79
  • 09:32 ETRegular-session high, $1.91
  • 09:56 ETRegular-session low, $1.56
  • 15:59 ETLast trade of the regular session, $1.76, -1.7% on the previous close of $1.79
  • Volume: 821K shares in regular hours, 298K before the open

BIVI opened at $1.90 after a premarket halt at $1.92, then briefly reached $1.91 before falling to a $1.56 low by 09:56 ET. It later recovered to finish at $1.76, below the previous close of $1.79. TapeRank’s read tied the move to BioVie’s Phase 2 ADDRESS-LC trial results, which showed positive Long COVID subgroup findings and an advantage over placebo on 21 of 22 endpoints, although the overall population did not achieve statistical significance and significant results were limited to prespecified subgroups.

WRITTEN THU OCT 15 2026 17:49 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE

FILINGS AND NEWS · 24H BEFORE THE MOVE

On the tape right now

WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY

01
ECGSURGING 0:05
79.71
▼ 29.3%
▼ 1.41%
41.0×
FAD
$6.2M
51.1M*
STRETCHED
02
CAVASURGING 0:00
64.78
▲ 7.4%
▲ 1.30%
9.3×
ORBHODVWH
$11.6M
116.8M*
UNEXPLAINED
03
URGNSURGING 0:00
29.16
▼ 15.2%
▼ 1.29%
15.6×
FAD
$1.4M
48.9M*
JUSTIFIED
04
MPTISURGING 0:00
64.15
▼ 1.5%
▲ 0.96%
23.8×
VWH
$637K
4.3M*
UNEXPLAINED
05
LSPDSURGING 0:00
11.52
▲ 4.9%
▼ 1.24%
16.5×
ORB
$426K
133.3M*
UNEXPLAINED
06
CRCTSURGING 0:00
8.90
▲ 49.2%
▼ 0.72%
15.1×
GAPORBVWHEXT
$395K
54.7M*
STRETCHED
07
BROSSURGING 0:00
43.97
▲ 0.9%
▼ 0.91%
4.0×
FAD
$4.3M
137.9M*
UNEXPLAINED
08
LMRICOOLING 1:35
12.85
▲ 14.5%
▲ 1.06%
132×
ORBHODVWH
$1.7M
—
UNEXPLAINED
Open the full list